ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1942

An Agnostic Evaluation of Serum Proteins Discriminates the Severity of Ultrasound Arthritis in SLE Patients
Abstract Number: 1943

Searching for subclinical synovitis and erosions in seropositive palindromic rheumatism: the added value of the ultrasonographic study of feet
Abstract Number: 1944

Musculoskeletal Ultrasound Clinic Referral Patterns and Joint Findings in a Tertiary Care Center amongst Patients with Elevated BMI and Inflammatory Arthritis
Abstract Number: 1945

Significance of Finger Joint Tenderness With or Without Swelling in Relation to MRI, Ultrasound, and X-Ray Findings in Psoriatic Arthritis_Final results
Abstract Number: 1946

Quantitative Imaging Analysis of Chest Computed Tomography in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1947

Coronary computed tomography incidental findings in rheumatoid arthritis.
Abstract Number: 1948

Enhanced Prediction of Knee Osteoarthritis Progression through Deep Learning-Based Multimodal Data Fusion
Abstract Number: 1949

Relapsing Polychondritis: Mimicking Asthma while Airways get Damaged
Abstract Number: 1950

Pericoronary fat enhancement in rheumatoid arthritis differs from controls and associates with coronary atherosclerosis independently of epicardial fat volume
Abstract Number: 1951

Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment
Abstract Number: 1952

Dermatoscopy Limitation and the Critical Role of Capillaroscopy in Systemic Sclerosis and Raynaud’s Phenomenon among African American Veterans
Abstract Number: 1953

Machine Learning-Based Classification of Raynaud’s Phenomenon and Autoimmune Diseases in Indeterminate Capillaroscopic Patterns
Abstract Number: 1954

Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation
Abstract Number: 1955

Regional variations in the relationship between pericoronary fat enhancement and atherosclerosis may reflect differences in local vascular inflammation in rheumatoid arthritis
Abstract Number: 1956

68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].